LTR Pharma (ASX:LTP) Operating Income: A$-10.76 Mil (TTM As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.58
! 1 Warning Sign
View Full Analysis

What is LTR Pharma Operating Income?

LTR Pharma ASX:LTP +6.48% 15 Operating Income is A$-10.76 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

LTR Pharma's Operating Income for the six months ended in Dec. 2025 was A$-6.07 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was A$-10.76 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. LTR Pharma's Operating Income for the six months ended in Dec. 2025 was A$-6.07 Mil. LTR Pharma's Revenue for the six months ended in Dec. 2025 was A$0.07 Mil. Therefore, LTR Pharma's Operating Margin % for the quarter that ended in Dec. 2025 was -8,202.70%.

LTR Pharma's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LTR Pharma's annualized ROC % for the quarter that ended in Dec. 2025 was -1,126.68%. LTR Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -26,391.30%.

LTR Pharma  (ASX:LTP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LTR Pharma's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-12.14 * ( 1 - 0% )/( (0.73099999999999 + 1.424)/ 2 )
=-12.14/1.0775
=-1,126.68 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=32.211 - 0.106 - ( 31.809 - max(0, 0.701 - 32.075+31.809))
=0.73099999999999

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=27.323 - 0.118 - ( 25.781 - max(0, 0.458 - 26.308+25.781))
=1.424

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

LTR Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.14/( ( (0.013 + max(-0.678, 0)) + (0.01 + max(0.069, 0)) )/ 2 )
=-12.14/( ( 0.013 + 0.079 )/ 2 )
=-12.14/0.046
=-26,391.30 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.004 + 0.02 + -0.00099999999999767) - (0.106 + 0 + 0.595)
=-0.678

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.507 + 0.02 + 0) - (0.118 + 0 + 0.34)
=0.069

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

LTR Pharma's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-6.07/0.074
=-8,202.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

LTR Pharma Operating Income Related Terms

LTR Pharma Operating Income Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Operating Income Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Operating Income
-0.03 -1.03 -1.44 -6.99 -7.47

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Income Get a 7-Day Free Trial -2.53 -4.46 -2.78 -4.69 -6.07
ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-10.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of A$-10.76 Mil mean?
LTR Pharma (ASX:LTP) has a Operating Income of A$-10.76 Mil as of Dec. 2025. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Operating Income too high?
LTR Pharma's current Operating Income is A$-10.76 Mil. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Operating Income compare to VRTX and REGN?
LTR Pharma's Operating Income of A$-10.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on LTR Pharma and its competitors. LTR Pharma's current Operating Income is A$-10.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Operating Income of A$-10.76 Mil. The current Operating Income is A$-10.76 Mil. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Operating Income is A$-10.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.58
Price